Jonathan Salcedo1,2, Monica Rosales3, Jeniffer S Kim4, Daisy Nuno5, Sze-Chuan Suen2,6, Alicia H Chang5. 1. Department of Pharmaceutical and Health Economics, School of Pharmacy, University of Southern California, Los Angeles, California, United States of America. 2. Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, United States of America. 3. Los Angeles County Department of Public Health, Office of Health Assessment and Epidemiology, Los Angeles, California, United States of America. 4. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America. 5. Los Angeles County Department of Public Health, Tuberculosis Control Program, Los Angeles, California, United States of America. 6. Daniel J. Epstein Department of Industrial and Systems Engineering, University of Southern California, Los Angeles, California, United States of America.
Abstract
BACKGROUND: Tuberculosis (TB) incidence in Los Angeles County, California, USA (5.7 per 100,000) is significantly higher than the U.S. national average (2.9 per 100,000). Directly observed therapy (DOT) is the preferred strategy for active TB treatment but requires substantial resources. We partnered with the Los Angeles County Department of Public Health (LACDPH) to evaluate the cost-effectiveness of AiCure, an artificial intelligence (AI) platform that allows for automated treatment monitoring. METHODS: We used a Markov model to compare DOT versus AiCure for active TB treatment in LA County. Each cohort transitioned between health states at rates estimated using data from a pilot study for AiCure (N = 43) and comparable historical controls for DOT (N = 71). We estimated total costs (2017, USD) and quality-adjusted life years (QALYs) over a 16-month horizon to calculate the incremental cost-effectiveness ratio (ICER) and net monetary benefits (NMB) of AiCure. To assess robustness, we conducted deterministic (DSA) and probabilistic sensitivity analyses (PSA). RESULTS: For the average patient, AiCure was dominant over DOT. DOT treatment cost $4,894 and generated 1.03 QALYs over 16-months. AiCure treatment cost $2,668 for 1.05 QALYs. At willingness-to-pay threshold of $150K/QALY, incremental NMB per-patient under AiCure was $4,973. In univariate DSA, NMB were most sensitive to monthly doses and vocational nurse wage; however, AiCure remained dominant. In PSA, AiCure was dominant in 93.5% of 10,000 simulations (cost-effective in 96.4%). CONCLUSIONS: AiCure for treatment of active TB is cost-effective for patients in LA County, California. Increased use of AI platforms in other jurisdictions could facilitate the CDC's vision of TB elimination.
BACKGROUND:Tuberculosis (TB) incidence in Los Angeles County, California, USA (5.7 per 100,000) is significantly higher than the U.S. national average (2.9 per 100,000). Directly observed therapy (DOT) is the preferred strategy for active TB treatment but requires substantial resources. We partnered with the Los Angeles County Department of Public Health (LACDPH) to evaluate the cost-effectiveness of AiCure, an artificial intelligence (AI) platform that allows for automated treatment monitoring. METHODS: We used a Markov model to compare DOT versus AiCure for active TB treatment in LA County. Each cohort transitioned between health states at rates estimated using data from a pilot study for AiCure (N = 43) and comparable historical controls for DOT (N = 71). We estimated total costs (2017, USD) and quality-adjusted life years (QALYs) over a 16-month horizon to calculate the incremental cost-effectiveness ratio (ICER) and net monetary benefits (NMB) of AiCure. To assess robustness, we conducted deterministic (DSA) and probabilistic sensitivity analyses (PSA). RESULTS: For the average patient, AiCure was dominant over DOT. DOT treatment cost $4,894 and generated 1.03 QALYs over 16-months. AiCure treatment cost $2,668 for 1.05 QALYs. At willingness-to-pay threshold of $150K/QALY, incremental NMB per-patient under AiCure was $4,973. In univariate DSA, NMB were most sensitive to monthly doses and vocational nurse wage; however, AiCure remained dominant. In PSA, AiCure was dominant in 93.5% of 10,000 simulations (cost-effective in 96.4%). CONCLUSIONS: AiCure for treatment of active TB is cost-effective for patients in LA County, California. Increased use of AI platforms in other jurisdictions could facilitate the CDC's vision of TB elimination.
Authors: Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel Journal: Value Health Date: 2012 Sep-Oct Impact factor: 5.725
Authors: Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon Journal: Clin Infect Dis Date: 2016-10-01 Impact factor: 9.079
Authors: Alistair Story; Richard S Garfein; Andrew Hayward; Valiantsin Rusovich; Andrei Dadu; Viorel Soltan; Alexandru Oprunenco; Kelly Collins; Rohit Sarin; Subhi Quraishi; Mukta Sharma; Giovanni Battista Migliori; Maithili Varadarajan; Dennis Falzon Journal: Emerg Infect Dis Date: 2016-03 Impact factor: 6.883
Authors: Richard S Garfein; Lin Liu; Jazmine Cuevas-Mota; Kelly Collins; Fatima Muñoz; Donald G Catanzaro; Kathleen Moser; Julie Higashi; Teeb Al-Samarrai; Paula Kriner; Julie Vaishampayan; Javier Cepeda; Michelle A Bulterys; Natasha K Martin; Phillip Rios; Fredric Raab Journal: Emerg Infect Dis Date: 2018-10 Impact factor: 6.883
Authors: R S Garfein; K Collins; F Muñoz; K Moser; P Cerecer-Callu; F Raab; P Rios; A Flick; M L Zúñiga; J Cuevas-Mota; K Liang; G Rangel; J L Burgos; T C Rodwell; K Patrick Journal: Int J Tuberc Lung Dis Date: 2015-09 Impact factor: 2.373